No Data
No Data
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $43
Capricor Therapeutics (CAPR) Receives a Buy From Oppenheimer
$1000 Invested In This Stock 5 Years Ago Would Be Worth $6,800 Today
Catalyst Watch: Netflix Earnings, Lenovo Tech Event, Paris Motor Show, and Eyes on Oil
Fastenal Posts Upbeat Earnings, Joins Wells Fargo, JPMorgan And Other Big Stocks Moving Higher On Friday
Capricor Reports Positive Data in Duchenne Muscular Dystrophy Study; Shares Rise
No Data
No Data